RIV-IND-5b2
cholinesterase inhibition of the RIV drug with antioxidant activity, biometal (Cu(II), Zn(II), Fe(III)) chelation properties, inhibition of amyloid- (A) aggregation (self- and Cu-induced) and of monoamine oxidases (MAOs), as well as neuroprotection capacity in cell models of AD and PD
General
Type : Monoamine-oxidase-inhibitor, Multitarget, Derivative of Rivastigmine, Indole, anti-Abeta-aggregation, Antioxidant
Chemical_Nomenclature :
Canonical SMILES : C1(=CC2=C(C=C1)[N]C(=C2)C(NCC3=CC(=CC=C3)OC(N(CC)C)=O)=O)O
InChI : InChI=1S\/C20H21N3O4\/c1-3-23(2)20(26)27-16-6-4-5-13(9-16)12-21-19(25)18-11-14-10-15(24)7-8-17(14)22-18\/h4-11,22,24H,3,12H2,1-2H3,(H,21,25)
InChIKey : NZBWGANKXCZNRW-UHFFFAOYSA-N
Other name(s) :
Target
References (2)
| Title : Exploiting the potential of rivastigmine-melatonin derivatives as multitarget metal-modulating drugs for neurodegenerative diseases - Dias_2024_J.Inorg.Biochem_262_112734 |
| Author(s) : Dias I , Bon L , Banas A , Chavarria D , Borges F , Guerreiro-Oliveira C , Cardoso SM , Sanna D , Garribba E , Chaves S , Santos MA |
| Ref : J Inorg Biochem , 262 :112734 , 2024 |
| Abstract : |
| PubMedSearch : Dias_2024_J.Inorg.Biochem_262_112734 |
| PubMedID: 39378762 |
| Title : New Multitarget Rivastigmine-Indole Hybrids as Potential Drug Candidates for Alzheimer's Disease - Bon_2024_Pharmaceutics_16_ |
| Author(s) : Bon L , Banas A , Dias I , Melo-Marques I , Cardoso SM , Chaves S , Santos MA |
| Ref : Pharmaceutics , 16 : , 2024 |
| Abstract : |
| PubMedSearch : Bon_2024_Pharmaceutics_16_ |
| PubMedID: 38399339 |